This bill mandates the commissioner of the department of health and human services, or their designee, to compile a report on the availability of mifepristone and misoprostol, which are medications used in medical abortions. The report, due by November 1, 2024, is to include potential actions to protect and expand access to these medications, ways to increase outreach and education about access, and identification of barriers to protecting or expanding access. The bill specifies that the report should not diminish the department's existing authority or require activities that violate state or federal law.

The bill also states that no general funds will be appropriated for the completion of this report. Instead, the department is instructed to seek and apply for any appropriate grants and federal funds available for this purpose. The act is set to take effect upon its passage. The Legislative Budget Assistant has determined that the fiscal impact of the legislation will be less than $10,000 in FY 2025. There are no insertions or deletions marked in the provided text, indicating that the bill does not directly amend existing law but rather directs the creation of a new report.